Establishment Labs Holdings Inc. (NASDAQ:ESTA) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Shares of Establishment Labs Holdings Inc. (NASDAQ:ESTA) have received an average recommendation of “Moderate Buy” from the eight analysts that are presently covering the company, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and six have given a buy recommendation to the company. The average 1-year price target among analysts that have issued ratings on the stock in the last year is $86.8571.

Several equities research analysts have issued reports on the company. Stephens lifted their price target on Establishment Labs from $85.00 to $90.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 25th. JPMorgan Chase & Co. increased their price objective on Establishment Labs from $71.00 to $80.00 and gave the company an “overweight” rating in a research report on Wednesday, December 17th. Weiss Ratings reissued a “sell (e+)” rating on shares of Establishment Labs in a report on Monday, December 29th. Wall Street Zen upgraded Establishment Labs from a “hold” rating to a “buy” rating in a research report on Saturday, March 7th. Finally, Mizuho upped their target price on Establishment Labs from $90.00 to $100.00 and gave the stock an “outperform” rating in a research note on Wednesday, February 25th.

Establishment Labs Price Performance

Shares of NASDAQ:ESTA opened at $66.24 on Thursday. The company’s fifty day moving average price is $70.55 and its 200-day moving average price is $60.23. The company has a debt-to-equity ratio of 10.51, a current ratio of 3.04 and a quick ratio of 2.00. The firm has a market capitalization of $1.94 billion, a price-to-earnings ratio of -38.07 and a beta of 0.91. Establishment Labs has a one year low of $26.56 and a one year high of $83.31.

Establishment Labs (NASDAQ:ESTA) last posted its quarterly earnings data on Tuesday, February 24th. The company reported ($0.09) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.22) by $0.13. Establishment Labs had a negative net margin of 24.19% and a negative return on equity of 201.79%. The company had revenue of $64.62 million during the quarter, compared to the consensus estimate of $63.80 million. During the same period in the previous year, the firm posted ($1.19) EPS. The firm’s revenue was up 45.2% compared to the same quarter last year. On average, equities research analysts anticipate that Establishment Labs will post -2.41 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Establishment Labs

Several institutional investors and hedge funds have recently made changes to their positions in ESTA. Simplify Asset Management Inc. bought a new stake in Establishment Labs in the third quarter worth $1,555,000. Tejara Capital Ltd grew its stake in shares of Establishment Labs by 31.2% during the third quarter. Tejara Capital Ltd now owns 102,494 shares of the company’s stock valued at $4,201,000 after buying an additional 24,386 shares during the last quarter. Woodson Capital Management LP increased its holdings in shares of Establishment Labs by 113.3% in the third quarter. Woodson Capital Management LP now owns 480,000 shares of the company’s stock worth $19,675,000 after buying an additional 255,000 shares during the period. Hood River Capital Management LLC lifted its stake in shares of Establishment Labs by 138.2% in the 2nd quarter. Hood River Capital Management LLC now owns 53,124 shares of the company’s stock valued at $2,269,000 after acquiring an additional 30,825 shares during the last quarter. Finally, Affinity Asset Advisors LLC lifted its stake in shares of Establishment Labs by 19.6% in the 2nd quarter. Affinity Asset Advisors LLC now owns 334,863 shares of the company’s stock valued at $14,302,000 after acquiring an additional 54,863 shares during the last quarter. Institutional investors own 72.91% of the company’s stock.

About Establishment Labs

Establishment Labs Holdings Inc is a global medical technology company specializing in the design, development and manufacture of silicone gel breast implants for aesthetic and reconstructive surgery. The company’s proprietary portfolio is built around patient-focused safety, customization and innovation, offering solutions intended to enhance surgical outcomes and support clinical traceability.

The company’s flagship products fall under the Motiva® brand, which includes a range of ergonomic and round breast implants featuring SilkSurface® texturing and an embedded Q Inside® Safety microtransponder for unique implant identification.